-
Mashup Score: 2Health Care and Climate Change: Challenges and Pathways to Sustainable Health Care | Annals of Internal Medicine - 2 year(s) ago
In this article, the changes that health care stakeholders, from clinicians to policymakers, can make to reduce meaningful levels of emissions generated as part of health care delivery are discussed.
Source: Annals of Internal MedicineCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 1Health Care and Climate Change: Challenges and Pathways to Sustainable Health Care | Annals of Internal Medicine - 2 year(s) ago
In this article, the changes that health care stakeholders, from clinicians to policymakers, can make to reduce meaningful levels of emissions generated as part of health care delivery are discussed.
Source: Annals of Internal MedicineCategories: Cardiologists, Latest HeadlinesTweet-
Large hospitals account for fewer than 1% of all commercial buildings but consume 5.5% of total delivered energy in the commercial sector #decarbonization of the energy grid with reliable alternative energy source is crucial for #healthcare https://t.co/HYwmufCws9 https://t.co/3Gj5AnDSiH
-
-
Mashup Score: 0Health Care and Climate Change: Challenges and Pathways to Sustainable Health Care | Annals of Internal Medicine - 2 year(s) ago
In this article, the changes that health care stakeholders, from clinicians to policymakers, can make to reduce meaningful levels of emissions generated as part of health care delivery are discussed.
Source: Annals of Internal MedicineCategories: Cardiologists, Latest HeadlinesTweet-
#Healthcare and #ClimateChange: Challenges and Pathways to #Sustainable HealthCare @AnnalsofIM Collective thoughts with @SaurabhSDani @Sadeer_AlKindi & #SanjayRajagopalan @bethisraellahey @UH_RE_Institute Let's act now to transform healthcare delivery! https://t.co/RKY8v4rNLZ https://t.co/KySGNJqt6k
-
-
Mashup Score: 0Cardiovascular Drug Interactions With Nirmatrelvir/Ritonavir in Patients With COVID-19: JACC Review Topic of the Week - 2 year(s) ago
Nirmatrelvir-ritonavir (NMVr) is used to treat symptomatic, nonhospitalized patients with coronavirus disease-2019 (COVID-19) who are at high risk of …
Source: www.sciencedirect.comCategories: Cardiologists, Latest HeadlinesTweet-
#Paxlovid (very effective) may interact with common #CVD medications #CardioEd 1. May need to hold CV med if possible 2. May need to reduce the dose temporarily 3. If not feasible/practicle, look for alternative #COVID19 therapy. @JACCJournals @pfizer https://t.co/r6IblttoMJ https://t.co/UgVpr7UBtX
-
-
Mashup Score: 1Oral Nirmatrelvir and Ritonavir in Nonhospitalized Vaccinated Patients With Coronavirus Disease 2019 (COVID-19) - 2 year(s) ago
In this observational analysis of real-world data, treatment with nirmatrelvir plus ritonavir in nonhospitalized vaccinated patients at high risk of disease pro
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet-
@SaurabhSDani @TriNetX @gadi_lachman @GeorgeAbraham65 @PaulSaxMD @Ashish_Kumar_MD Thank you @TriNetX @gadi_lachman for the wonderful research platform & opportunity to present the real world data based timely study on #Paxlovid #Covid_19 @CIDJournal @IDSAInfo with @SaurabhSDani @PaulSaxMD @Bob_Wachter @GeorgeAbraham65 @McQHoya81 et al. https://t.co/rXfVxV02NL https://t.co/K9pSVvUcft
-
-
Mashup Score: 0Cardiovascular Drug Interactions With Nirmatrelvir/Ritonavir in Patients With COVID-19: JACC Review Topic of the Week - 2 year(s) ago
Nirmatrelvir-ritonavir (NMVr) is used to treat symptomatic, nonhospitalized patients with coronavirus disease-2019 (COVID-19) who are at high risk of …
Source: www.sciencedirect.comCategories: Cardiologists, Latest HeadlinesTweet-
New Deep Dive Into Paxlovid Interactions With CVD Meds @Medscape coverage our JACC article (Read our JACC paper at https://t.co/5sQiY1Nt5P) highlights the potential drug interactions and discuss strategies to minimize. https://t.co/d5wlH277eL via @Medscape
-
-
Mashup Score: 4Please wait whilst we redirect you - 2 year(s) ago
About ScienceDirectRemote accessShopping cartAdvertiseContact and supportTerms and conditionsPrivacy policyWe use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies.Copyright © 2022 Elsevier B.V. or its licensors or contributors. ScienceDirect® is a registered trademark of Elsevier B.V.ScienceDirect® is a registered trademark…
Source: www.sciencedirect.comCategories: Cardiologists, Latest HeadlinesTweet-
Does your patient need #Paxlovid for #COVID19 treatment? Do they take #CardioTwitter (CV) medications? We review Paxlovid & CV medications interactions & provide management guidance.@JACCJournals @ACCinTouch @sonuabrahammd @SaurabhSDani @bethisraellahey https://t.co/A06ksti9sF https://t.co/zp4Vi486QH
-
-
Mashup Score: 1Impact of Social Vulnerability on Comorbid Cancer and Cardiovascular Disease Mortality in the United States: - 2 year(s) ago
Abstract Background Racial and social disparities exist in outcomes related to cancer and cardiovascular disease (CVD). Objectives The aim of this cross-sectional study was to study the impact of s…
Source: JACC: CardioOncologyCategories: Cardiologists, Latest HeadlinesTweet-
@AmiBhattMD @ACCinTouch @MGHHeartHealth @GiselleSA_MDPhD @drmalissawood @ddefariayeh Disparities and social vulnerability affect patients with #CVD and comorbid #cancer even more than patients with cancer or cvd alone. #cardioonc. See our @JACCJournals article https://t.co/s7cAeQdTLt
-
-
Mashup Score: 2
Abstract The field of cardio-oncology was born from the necessity for recognition and management of cardiovascular diseases among patients with cancer. This need for this specialty continues to gro…
Source: JACC: CardioOncologyCategories: Cardiologists, Latest HeadlinesTweet-
Are all cardiotoxicities bad enough to stop #cancer therapies? Can we put a cart before the horse? Our efforts to conceptualize "Permissive Cardiotoxicity" in #cardioonc https://t.co/fFfAdvnMTz @charlesporter99 @DrTochiOkwuosa #DanLenihan @sdent_duke et al. @ICOSociety https://t.co/rgkqJdr9mC
-
-
Mashup Score: 0Oral Nirmatrelvir and Ritonavir in Non-hospitalized Vaccinated Patients with Covid-19 - 2 year(s) ago
AbstractBackground. Treatment of coronavirus disease-2019 (Covid-19) with nirmatrelvir plus ritonavir (NMV-r) in high-risk non-hospitalized unvaccinated patient
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet-
Our study (@TriNetX) shows: In non-hospitalized VACCINATED high-risk patients with #Covid_19, #Paxlovid improved clinical outcomes and reduced resource utilization. @PaulSaxMD @Bob_Wachter @GeorgeAbraham65 @McQHoya81 @SaurabhSDani @CIDJournal @IDSAInfo https://t.co/xc9HxHRFnF https://t.co/44AZTfrCbV
-
To tackle #Climate change, #Healthcare organizations need to map the sources & magnitude of #GHG emissions (https://t.co/twcbLIb4yG) Scope 1: Direct emissions-7% Scope 2: Indirect emissions (energy suppliers)-11% Scope 3: Supply chain-82% @Sadeer_AlKindi @SaurabhSDani https://t.co/zwu8PJGgzh